EIK1001 in NSCLC shows durable effect and good tolerability
Eikon Therapeutics reported updated clinical data for its TLR7/8 agonist EIK1001. In NSCLC patients, the combination with pembrolizumab and chemotherapy demonstrated a durable effect with an encouraging safety profile, a key differentiator from previous therapies. The company also noted their ongoing Phase 2/3 trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed